Literature DB >> 21890201

Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.

Ester M Orlandi, Barbara Rocca, Anna S Pazzano, Stefano Ghio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21890201     DOI： 10.1016/j.leukres.2011.08.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  18 in total

1.  Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.

Authors:  J-C Kim; S-H Shin; H G Yi; S-H Kim; S-I Woo; D-H Kim; K-S Park; J Kwan
Journal:  Herz       Date:  2013-02-23       Impact factor: 1.443

2.  Tirosine kinase inhibitors adverse events.

Authors:  Leonardo Campiotti; Andrea Maresca; Luigina Guasti; Anna Maria Grandi
Journal:  Oncologist       Date:  2014-03

Review 3.  Drug-induced pulmonary arterial hypertension: a review.

Authors:  Lohit Garg; Ghulam Akbar; Sahil Agrawal; Manyoo Agarwal; Leila Khaddour; Rishin Handa; Aakash Garg; Mahek Shah; Brijesh Patel; Bhavinkumar D Dalal
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 4.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

Review 5.  Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Authors:  Kuan-Liang Liu; Jen-Shi Chen; Shin-Cheh Chen; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2013-07       Impact factor: 2.672

6.  Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertension.

Authors:  Chandran Nagaraj; Bi Tang; Bence M Nagy; Rita Papp; Pritesh P Jain; Leigh M Marsh; Andrea L Meredith; Bahil Ghanim; Walter Klepetko; Grazyna Kwapiszewska; E Kenneth Weir; Horst Olschewski; Andrea Olschewski
Journal:  Eur Respir J       Date:  2016-08-18       Impact factor: 16.671

Review 7.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

8.  Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.

Authors:  Dariusz Zakrzewski; Ilona Seferynska; Krzysztof Warzocha; Tomasz Hryniewiecki
Journal:  Int J Hematol       Date:  2012-05-26       Impact factor: 2.490

9.  A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer.

Authors:  Humera Khurshid; Thomas Dipetrillo; Thomas Ng; Kalyan Mantripragada; Ariel Birnbaum; David Berz; Kathy Radie-Keane; Kimberly Perez; Maria Constantinou; Denise Luppe; Andrew Schumacher; Kara Leonard; Howard Safran
Journal:  Front Oncol       Date:  2012-05-31       Impact factor: 6.244

Review 10.  A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Authors:  Elias Jabbour; Jeffrey H Lipton
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.